VOR

Vor Biopharma Inc.

• Dow Jones·05/18 18:00

  Vor Biopharma Price Target Maintained With a $31.00/Share by HC Wainwright & Co.

• Benzinga·05/18 17:49

  HC Wainwright & Co. Reiterates Buy on Vor Biopharma, Maintains $31 Price Target

• TipRanks·05/18 10:15

  Vor Biopharma: Buy Rating Reiterated on Strong Telitacicept Validation and Autoimmune Growth Runway; $31 Price Target Unchanged

• Simply Wall St·05/15 11:35

  Companies Like Vor Biopharma (NASDAQ:VOR) Are In A Position To Invest In Growth

• TipRanks·05/14 17:08

  Vor Bio price target raised to $18 from $15 at Wedbush

• Dow Jones·05/14 13:30

  Vor Biopharma Price Target Raised to $18.00/Share From $15.00 by Wedbush

• Dow Jones·05/14 13:30

  Vor Biopharma Is Maintained at Neutral by Wedbush

• Benzinga·05/14 13:19

  Wedbush Maintains Neutral on Vor Biopharma, Raises Price Target to $18

• TipRanks·05/14 10:20

  Analysts’ Opinions Are Mixed on These Healthcare Stocks: Staar Surgical (STAA), Halozyme (HALO) and Vor Biopharma (VOR)

• TipRanks·05/13 18:30

  Analysts Are Bullish on These Healthcare Stocks: Protara Therapeutics (TARA), Vor Biopharma (VOR)

• Benzinga·05/13 12:57

  Vor Biopharma Q1 Adj. EPS $(0.73) Beats $(0.78) Estimate

• Reuters·05/13 12:38

  Vor Biopharma Q1 net loss widens

• Seeking Alpha·05/13 12:35

  Vor Biopharma reports Q1 results

• Dow Jones·05/13 12:33

  *Vor Biopharma: Enrollment on Track for Phase 3 UPSTREAM MG Trial of Telitacicept in Generalized Myasthenia Gravis Patients With Topline Results Anticipated in 1H27 >VOR

• PUBT·05/13 12:32

  Vor Bio Q1 FY26 net loss more than doubled to $219.6 million